Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer

References

• Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33:207-14; PMID:22398146; http://dx.doi.org/10.1016/j.tips.2012.01.005
   PubMed Web of Science ®Google Scholar
• Noman MZ, Messai Y, Carre T, Akalay I, Meron M, Janji B, Hasmim M, Chouaib S. Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit Rev Immunol 2011; 31:357-77; PMID:22142164; http://dx.doi.org/10.1615/CritRevImmunol.v31.i5.10
   PubMed Web of Science ®Google Scholar
• Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 2012; 3:21; PMID:22566905; http://dx.doi.org/10.3389/fimmu.2012.00021
   PubMed Web of Science ®Google Scholar
• Messai Y, Noman MZ, Hasmim M, Janji B, Tittarelli A, Boutet M, Baud V, Viry E, Billot K, Nanbakhsh A et al. ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy. Cancer Res 2014; 74:6820-32; PMID:25297632; http://dx.doi.org/10.1158/0008-5472.CAN-14-0303
   PubMed Web of Science ®Google Scholar
• Baginska J, Viry E, Berchem G, Poli A, Noman MZ, van Moer K, Medves S, Zimmer J, Oudin A, Niclou SP et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc Natl Acad Sci USA 2013; 110:17450-5; PMID:24101526; http://dx.doi.org/10.1073/pnas.1304790110
   PubMed Web of Science ®Google Scholar
• Viry E, Baginska J, Berchem G, Noman MZ, Medves S, Chouaib S, Janji B. Autophagic degradation of GZMB/granzyme B: a new mechanism of hypoxic tumor cell escape from natural killer cell-mediated lysis. Autophagy 2014; 10:173-5; PMID:24248158; http://dx.doi.org/10.4161/auto.26924
   PubMed Web of Science ®Google Scholar
• Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014; 211:781-90; PMID:24778419; http://dx.doi.org/10.1084/jem.20131916
   PubMed Web of Science ®Google Scholar
• Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci 2010; 123:1603-11; PMID:20445011; http://dx.doi.org/10.1242/jcs.064386
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14:1014-22; PMID:24048123; http://dx.doi.org/10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Antonyak MA, Cerione RA. Microvesicles as mediators of intercellular communication in cancer. Methods Mol Biol 2014; 1165:147-73; PMID:24839024
   PubMedGoogle Scholar
• D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Gen Dev 2012; 26:1287-99; PMID:22713869; http://dx.doi.org/10.1101/gad.192351.112
   PubMed Web of Science ®Google Scholar
• Martins VR, Dias MS, Hainaut P. Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol 2013; 25:66-75; PMID:23165142; http://dx.doi.org/10.1097/CCO.0b013e32835b7c81
   PubMed Web of Science ®Google Scholar
• Schifferli JA. Microvesicles are messengers. Semin Immunopathol 2011; 33:393-4; PMID:21590325; http://dx.doi.org/10.1007/s00281-011-0276-6
   PubMed Web of Science ®Google Scholar
• Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002; 360:295-305; PMID:12147373; http://dx.doi.org/10.1016/S0140-6736(02)09552-1
   PubMed Web of Science ®Google Scholar
• Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7:297-303; PMID:11231627; http://dx.doi.org/10.1038/85438
   PubMed Web of Science ®Google Scholar
• Lv LH, Wan YL, Lin Y, Zhang W, Yang M, Li GL, Lin HM, Shang CZ, Chen YJ, Min J. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem 2012; 287:15874-85; PMID:22396543; http://dx.doi.org/10.1074/jbc.M112.340588
   PubMed Web of Science ®Google Scholar
• Clayton A, Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis 2005; 34:206-13; PMID:15885603; http://dx.doi.org/10.1016/j.bcmd.2005.03.003
   PubMed Web of Science ®Google Scholar
• Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 2011; 96:1302-9; PMID:21606166; http://dx.doi.org/10.3324/haematol.2010.039743
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 2013; 41:245-51; PMID:23356291; http://dx.doi.org/10.1042/BST20120265
   PubMed Web of Science ®Google Scholar
• King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC cancer 2012; 12:421; PMID:22998595; http://dx.doi.org/10.1186/1471-2407-12-421
   PubMed Web of Science ®Google Scholar
• Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringner M, Morgelin M, Bourseau-Guilmain E, Bengzon J, Belting M. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci USA 2013; 110:7312-7; PMID:23589885; http://dx.doi.org/10.1073/pnas.1220998110
   PubMed Web of Science ®Google Scholar
• Wang T, Gilkes DM, Takano N, Xiang L, Luo W, Bishop CJ, Chaturvedi P, Green JJ, Semenza GL. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad Sci USA 2014; 111:E3234-42; PMID:24938788; http://dx.doi.org/10.1073/pnas.1410041111
   PubMed Web of Science ®Google Scholar
• Noman MZ, Buart S, Van Pelt J, Richon C, Hasmim M, Leleu N, Suchorska WM, Jalil A, Lecluse Y, El Hage F et al. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 2009; 182:3510-21; PMID:19265129; http://dx.doi.org/10.4049/jimmunol.0800854
   PubMed Web of Science ®Google Scholar
• El-Andaloussi S, Lee Y, Lakhal-Littleton S, Li J, Seow Y, Gardiner C, Alvarez-Erviti L, Sargent IL, Wood MJ. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat protoc 2012; 7:2112-26; PMID:23154783; http://dx.doi.org/10.1038/nprot.2012.131
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:503-10; PMID:18425107; http://dx.doi.org/10.1038/ni1582
   PubMed Web of Science ®Google Scholar
• Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Ann Rev Immunol 2013; 31:227-58; PMID:23516982; http://dx.doi.org/10.1146/annurev-immunol-020711-075005
   PubMed Web of Science ®Google Scholar
• Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-oncology 2010; 12:7-13; PMID:20150362; http://dx.doi.org/10.1093/neuonc/nop009
   PubMed Web of Science ®Google Scholar
• Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, Mami-Chouaib F, Chouaib S. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 2012; 72:4629-41; PMID:22962263; http://dx.doi.org/10.1158/0008-5472.CAN-12-1383
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhao L, Li D, Yin Y, Zhang C-Y, Li J, Zhang Y. Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development. Protein Cell 2013; 4:932-41; PMID:24203759; http://dx.doi.org/10.1007/s13238-013-3092-z
   PubMed Web of Science ®Google Scholar
• Muturi HT, Dreesen JD, Nilewski E, Jastrow H, Giebel B, Ergun S, Singer BB. Tumor and endothelial cell-derived microvesicles carry distinct CEACAMs and influence T-Cell behavior. PloS one 2013; 8:e74654; PMID:24040308; http://dx.doi.org/10.1371/journal.pone.0074654
   PubMed Web of Science ®Google Scholar
• Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M, Reynolds PN, Jersmann H, Hodge S. Lung cancer is associated with decreased expression of perforin, granzyme B and IFNgamma by infiltrating lung tissue T cells, NKT-like and NK cells. Clin Exp Immunol 2014; 178(1):79-85; PMID:24894428; http://dx.doi.org/10.1111/cei.12392
   PubMed Web of Science ®Google Scholar
• Greenberg E, Nemlich Y, Markel G. MicroRNAs in cancer: lessons from melanoma. Curr Pharm Des 2014; 20(33):5246-59; PMID:24479804; http://dx.doi.org/10.2174/1381612820666140128210105
   PubMed Web of Science ®Google Scholar
• Schatton T, Scolyer RA, Thompson JF, Mihm MC, Jr. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Method Mol Biol 2014; 1102:287-324; PMID:24258985; http://dx.doi.org/10.1007/978-1-62703-727-3_16.
   PubMedGoogle Scholar
• Maeda N, Yoshimura K, Yamamoto S, Kuramasu A, Inoue M, Suzuki N, Watanabe Y, Maeda Y, Kamei R, Tsunedomi R et al. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients. Ann Surg Oncol 2014; 21 Suppl 4:S546-54; PMID:24562936; http://dx.doi.org/10.1245/s10434-014-3564-2
   PubMedGoogle Scholar
• Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PloS one 2014; 9:e88557; PMID:24551119; http://dx.doi.org/10.1371/journal.pone.0088557
   PubMed Web of Science ®Google Scholar
• Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Method 2004; 294:15-22; PMID:15604012; http://dx.doi.org/10.1016/j.jim.2004.08.008
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001; 7:1118-22; PMID:11590434; http://dx.doi.org/10.1038/nm1001-1118
   PubMed Web of Science ®Google Scholar
• Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005; 8:369-80; PMID:16286245; http://dx.doi.org/10.1016/j.ccr.2005.10.012
   PubMed Web of Science ®Google Scholar
• Hayashi H, Inoue Y, Tsutsui H, Okamura H, Nakanishi K, Onozaki K. TGFbeta down-regulates IFN-gamma production in IL-18 treated NK cell line LNK5E6. Biochem Biophys Res Commun 2003; 300:980-5; PMID:12559970; http://dx.doi.org/10.1016/S0006-291X(02)02939-X
   PubMed Web of Science ®Google Scholar
• Chandran PA, Keller A, Weinmann L, Adel Seida A, Braun M, Andreev K, Fischer B, Horn E, Schwinn S, Junker M et al. The TGF-beta-inducible miR-23a cluster attenuates IFN-gamma levels and antigen-specific cytotoxicity in human CD8+ T cells. J Leukoc Biol 2014; 96(4):633-45; PMID:25030422; http://dx.doi.org/10.1189/jlb.3A0114-025R
   PubMed Web of Science ®Google Scholar